Histone deacetylase inhibitors: understanding a new wave of anticancer agents

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Cancer exhibits significant epigenetic alterations, including DNA methylation and histone modifications.
• Histone deacetylase inhibitors (HDACis) are a promising class of epigenetic drugs targeting these modifications.
• HDACis induce histone acetylation, impacting chromatin structure and gene expression.

Purpose of the Study:

• To explore the therapeutic potential of HDAC inhibitors in cancer treatment.
• To investigate the mechanisms of action of HDAC inhibitors, including tumor-suppressor gene reactivation.
• To evaluate the tolerability and potential combination therapies involving HDAC inhibitors.

Main Methods:

• Review of current research on epigenetic alterations in cancer.
• Analysis of the biochemical and biologic properties of HDAC inhibitors.
• Examination of data from Phase I clinical trials of HDAC inhibitors.

Main Results:

• HDAC inhibitors reactivate dormant tumor-suppressor genes like p21WAF1.
• HDAC inhibitors demonstrate pleiotropic effects, including differentiation, cell-cycle arrest, and apoptosis.
• Phase I clinical trials indicate HDAC inhibitors are generally well-tolerated.

Conclusions:

• HDAC inhibitors represent a promising therapeutic strategy for cancer.
• Combination therapy with classical chemotherapy or DNA-demethylating agents may enhance efficacy.
• Further clinical validation is warranted to establish the full therapeutic potential of HDAC inhibitors.